Serenoa repens for benign prostatic hyperplasia

Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?

“…This data correlates with the results reported in other series 14,16 . After 6 months, all the treatment groups induced practically the same mean reduction in total IPSS (-4.6 vs -6.1 vs -4.9 points) with 2/3 of men responding to the treatment by a decrease of 3 points or more.…”

Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?

“…This data correlates with the results reported in other series 14,16 . After 6 months, all the treatment groups induced practically the same mean reduction in total IPSS (-4.6 vs -6.1 vs -4.9 points) with 2/3 of men responding to the treatment by a decrease of 3 points or more.…”

Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial

“…Using a different urinary symptom score to that used in the present study, a weighted mean difference of − 1.41 points (95% CI, − 2.52, 0.30; scale range 0–19) was reported, indicating a clear treatment effect [14]. This is in contrast to the present result, i.e.…”

“…The main hypotheses for this study were that in patients treated with S. repens extract, but not with placebo, the IPSS would decrease and peak urinary flow rate and sexual function would not decline. The results are partly unexpected, particularly for the IPSS and urine flow, which apparently improved with S. repens treatment, as assessed in a meta‐analysis by the Cochrane Library [14]. In favour of the present results, the study used randomization and blinding, had a high compliance and low withdrawal rate (7%) and the dosage was also comparable to that in other studies.…”

“…For the peak urinary flow rate, the data summarized in the meta‐analysis [14] indicated a weighted mean (95% CI) improvement of 1.93 (0.72–3.14), again indicating a clear treatment effect, in contrast to the present result. Obtaining flow rates from men when they had a full bladder was a challenging requirement.…”

Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review

“…In previous Cochrane reviews [5,27], first published in 1998, we reported that Serenoa repens extracts provided mild improvement of urological symptoms. However, the trials evaluated were mostly under‐powered, short‐term (<6 months), had variable study designs, outcomes, and used unvalidated symptom‐scale scores.…”

Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?

“…This data correlates with the results reported in other series 14,16 . After 6 months, all the treatment groups induced practically the same mean reduction in total IPSS (-4.6 vs -6.1 vs -4.9 points) with 2/3 of men responding to the treatment by a decrease of 3 points or more.…”

Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial

“…Using a different urinary symptom score to that used in the present study, a weighted mean difference of − 1.41 points (95% CI, − 2.52, 0.30; scale range 0–19) was reported, indicating a clear treatment effect [14]. This is in contrast to the present result, i.e.…”

“…The main hypotheses for this study were that in patients treated with S. repens extract, but not with placebo, the IPSS would decrease and peak urinary flow rate and sexual function would not decline. The results are partly unexpected, particularly for the IPSS and urine flow, which apparently improved with S. repens treatment, as assessed in a meta‐analysis by the Cochrane Library [14]. In favour of the present results, the study used randomization and blinding, had a high compliance and low withdrawal rate (7%) and the dosage was also comparable to that in other studies.…”

“…For the peak urinary flow rate, the data summarized in the meta‐analysis [14] indicated a weighted mean (95% CI) improvement of 1.93 (0.72–3.14), again indicating a clear treatment effect, in contrast to the present result. Obtaining flow rates from men when they had a full bladder was a challenging requirement.…”

Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review

“…In previous Cochrane reviews [5,27], first published in 1998, we reported that Serenoa repens extracts provided mild improvement of urological symptoms. However, the trials evaluated were mostly under‐powered, short‐term (<6 months), had variable study designs, outcomes, and used unvalidated symptom‐scale scores.…”

Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?

“…This data correlates with the results reported in other series 14,16 . After 6 months, all the treatment groups induced practically the same mean reduction in total IPSS (-4.6 vs -6.1 vs -4.9 points) with 2/3 of men responding to the treatment by a decrease of 3 points or more.…”

Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial

“…Using a different urinary symptom score to that used in the present study, a weighted mean difference of − 1.41 points (95% CI, − 2.52, 0.30; scale range 0–19) was reported, indicating a clear treatment effect [14]. This is in contrast to the present result, i.e.…”

“…The main hypotheses for this study were that in patients treated with S. repens extract, but not with placebo, the IPSS would decrease and peak urinary flow rate and sexual function would not decline. The results are partly unexpected, particularly for the IPSS and urine flow, which apparently improved with S. repens treatment, as assessed in a meta‐analysis by the Cochrane Library [14]. In favour of the present results, the study used randomization and blinding, had a high compliance and low withdrawal rate (7%) and the dosage was also comparable to that in other studies.…”

“…For the peak urinary flow rate, the data summarized in the meta‐analysis [14] indicated a weighted mean (95% CI) improvement of 1.93 (0.72–3.14), again indicating a clear treatment effect, in contrast to the present result. Obtaining flow rates from men when they had a full bladder was a challenging requirement.…”

Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review

“…In previous Cochrane reviews [5,27], first published in 1998, we reported that Serenoa repens extracts provided mild improvement of urological symptoms. However, the trials evaluated were mostly under‐powered, short‐term (<6 months), had variable study designs, outcomes, and used unvalidated symptom‐scale scores.…”